Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Josef Jampilek

Josef Jampilek

Comenius University, Slovakia

Title: Perspectives of antifungal drug discovery

Biography

Biography: Josef Jampilek

Abstract

The vast majority of the known 2 million fungal species are strict saprophytes, but some of them can attack humans, animals and plants. It is estimated that 270,000 fungal species are associated with plants, and 325 fungal species, common in the environment, are known to infect humans. Human fungal infections range from superficial nail and skin infections to invasive, systemic infections that are really harmful to health and life. Human fungal infections generally receive less attention than bacterial and viral diseases, since the incidence of systemic fungal infections is considerably lower than that of superficial infections, however, mortality rates from invasive fungal infections are very high, often exceeding 50%, despite the use of antifungal drugs. Early diagnosis of disease and identification of the fungal pathogen remain crucial for the treatment of invasive fungal infections, because the efficacy of currently used drugs is limited by issues with administration route, narrow treatment window, activity spectrum, bioavailability, toxicity, drug resistance and cost. The increase in the number of fungal infections and the occurrence of new fungal opportunistic species is caused by general immunosuppression of the population. Agents can be divided into nonspecific antifungals and targeted site-specific antifungals.Although there is a relatively big number of topical antifungal medications, only about 12 drugs were approved for the treatment of systemic fungal infections (ATC J02A). Development of resistance/cross-resistance to commonly used drugs and multidrug-resistance of fungal pathogens constitute serious problems, and it is evident that new systemic (preferably orally administered) antifungal drugs are urgently needed.

Speaker Presentations

Speaker PPTs Click Here